- ISIN
- US78349D1072
- CUSIP
- 78349D107
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Jul 30, 2021
Highlights
- Market Cap
- $197.86M
- Enterprise Value
- $192.61M
- EPS (TTM)
- -$1.14
- Total Revenue (TTM)
- $127.48M
- Gross Profit (TTM)
- $98.18M
- EBITDA (TTM)
- -$50.09M
- Year Range
- $4.70 - $16.00
- Target Price
- $10.75
- ROA (TTM)
- -15.34%
- ROE (TTM)
- -17.45%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RXST Performance Chart
RxSight, Inc. (RXST) is down 54.0% since the beginning of the year. At $5 per share, RXST is trading 70.1% below its 52-week high of $16.
Loading charts...
Returns By Period
RxSight, Inc. (RXST) has returned -54.03% so far this year and -69.70% over the past 12 months.
RxSight, Inc.
- 1D
- -3.04%
- 1M
- -35.09%
- YTD
- -54.03%
- 6M
- -59.61%
- 1Y
- -69.70%
- 3Y*
- -43.12%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
RXST Monthly Returns History
Based on dividend-adjusted daily data since Jul 30, 2021, RXST's average daily return is 0.00%, while the average monthly return is -0.51%.
Historically, 44% of months were positive and 56% were negative. The best month was Nov 2023 with a return of +36.2%, while the worst month was Apr 2025 at -41.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, RXST closed higher 49% of trading days. The best single day was Jan 10, 2022 with a return of +28.2%, while the worst single day was Apr 3, 2025 at -37.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -16.60% | -13.92% | -17.65% | 14.77% | -24.61% | -10.13% | -54.03% | ||||||
| 2025 | -1.48% | -16.27% | -10.97% | -41.70% | 3.87% | -14.98% | -40.15% | 16.20% | -0.55% | -2.22% | 29.92% | -8.76% | -69.69% |
| 2024 | 12.87% | 19.91% | -5.48% | 1.07% | 12.16% | 2.91% | -23.93% | 23.20% | -12.34% | 2.49% | -7.46% | -26.66% | -14.73% |
| 2023 | 10.50% | -2.00% | 21.57% | 7.31% | 36.15% | 18.18% | 15.87% | -13.07% | -3.86% | -20.62% | 36.22% | 33.69% | 218.23% |
| 2022 | -8.53% | 30.42% | -7.75% | -0.89% | 11.33% | 3.07% | 6.25% | -16.38% | -4.08% | 3.67% | 2.65% | -0.78% | 12.62% |
| 2021 | -3.87% | -17.62% | -5.45% | -9.43% | 3.69% | -29.69% |
Benchmark Metrics
RxSight, Inc. has an annualized alpha of -15.30%, beta of 1.28, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since August 02, 2021.
- This stock participated in 196.74% of S&P 500 Index downside but only 82.09% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -15.30%
- Beta
- 1.28
- R²
- 0.10
- Upside Capture
- 82.09%
- Downside Capture
- 196.74%
Return for Risk
Risk / Return Rank
RXST ranks 4 for risk / return — in the bottom 4% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for RxSight, Inc. (RXST) and compare them to S&P 500 Index.
| RXST | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.95 | 2.24 | -3.19 |
Sortino ratioReturn per unit of downside risk | -1.54 | 3.07 | -4.62 |
Omega ratioGain probability vs. loss probability | 0.80 | 1.41 | -0.61 |
Calmar ratioReturn relative to maximum drawdown | -1.01 | 2.93 | -3.93 |
Martin ratioReturn relative to average drawdown | -1.54 | 13.52 | -15.07 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the RxSight, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the RxSight, Inc. was 92.55%, occurring on Jun 3, 2026. The portfolio has not yet recovered.
The current RxSight, Inc. drawdown is 92.55%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -92.55%Jun 2026 | 2y 18d | — | 2y 19dMay 2024 - now |
Bear market2022 | -48.21%Jan 2022 | 5mo 7d | 1y 3mo | 1y 8moAug 2021 - Apr 2023 |
2023 bear market2023 | -37.34%Oct 2023 | 3mo | 1mo 7d | 4mo 7dAug 2023 - Dec 2023 |
2024 bear market2024 | -20.23%Mar 2024 | 15d | 1mo 19d | 2mo 4dFeb 2024 - May 2024 |
2024 correction2024 | -13.18%Jan 2024 | 6d | 5d | 11dDec 2023 - Jan 2024 |
Drawdown Indicators
| RXST | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.55% | -56.78% | -35.77% |
Max Drawdown (1Y)Largest decline over 1 year | -69.47% | -9.10% | -60.37% |
Max Drawdown (3Y)Largest decline over 3 years | -92.55% | -18.90% | -73.65% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -92.55% | -0.74% | -91.81% |
Average DrawdownAverage peak-to-trough decline | -36.61% | -10.72% | -25.89% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 45.50% | 1.97% | +43.53% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of RxSight, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how RxSight, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for RXST relative to other companies in the Medical Devices industry. Currently, RXST has a P/S ratio of 1.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for RXST in comparison with other companies in the Medical Devices industry. Currently, RXST has a P/B value of 0.7. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RXST
Add RxSight, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RXST